

## Prémiový dluhový cenný papír VACCINATION AUTOCALL

ISIN: XS2364764303

## Overview


Date: 2024/07/26 11:05:00

|              |     |
|--------------|-----|
| Bid          | Ask |
| <b>97.88</b> | -   |

|            |              |
|------------|--------------|
| Difference | 0.51% (0.50) |
|------------|--------------|

## General attributes

|                       |                            |
|-----------------------|----------------------------|
| Type of bond          | Structured bonds and notes |
| Bond style            | senior                     |
| Issuer type           | financial institution      |
| Country of issue      | DE                         |
| Current coupon        | -                          |
| Coupon style          | variable                   |
| Coupon payment date   | -                          |
| Coupon payment period | at maturity                |
| Value date            | 2021/10/11                 |
| Maturity              | 2024/10/11                 |
| Repayment value       | 0.00                       |
| Currency              | CZK                        |
| Nominal value         | 10,000                     |
| Accrued Interest      | -                          |
| Investor tolerance    | <u>7 (scale 1-7)</u>       |



The chart is composed of values which are the arithmetic average values of bid / ask (MID) from previous working day. Performances under 12 month have only little informative value. Information about previous performance does not guarantee future performance.

Source: Česká spořitelna, a. s.

### + Advantages

What does the Prémiový dluhový cenný papír VACCINATION AUTOCALL offer?

- Possibility to obtain an interesting total yield of up to 24% for 3 years.
- PDCP VACCINATION AUTOCALL can be automatically repaid early already after the first year of its duration or subsequently the following year if at the observation date the individual underlying shares are at or above the valid barrier for early repayment.

### ! Details you should be aware of

Please note that the target market of this investment instrument is listed below. If you do not meet any of the listed parameters, you may be outside the specified target market!

The target market defines the set of investors (retail clients) for whom the investment product is intended.

This investment product is intended for investors who:

- have sufficient knowledge and/or experience

- Attractive barrier level of 55% of the initial value (see Note2) of the individual underlying shares for payout of the yield and nominal value of PDCP VACCINATION AUTOCALL at the date of fixing the closing value of individual underlying shares.
  - Additional protective mechanism for payout of the nominal value of PDCP VACCINATION AUTOCALL at its maturity date.
  - Barrier for automatic early repayment is decreasing over in time: 90% (after a year), 80% (after two years).
  - PDCP VACCINATION AUTOCALL is issued in Czech crowns and the investor does not bear the currency risk.
  - Electronic version of the Basic Prospectus is published on the Issuer's website <https://www.goldmansachs.com> or on [www.investicnicentrum.cz/prospekty](http://www.investicnicentrum.cz/prospekty).
  - Electronic version of the Notification of Key Information is published on the website <https://www.gspriips.eu> or you can find it on the investment portal [www.investicnicentrum.cz](http://www.investicnicentrum.cz).
- regarding structured products and shares.
- seek investment profit
  - are able to accept a level of risk that is in accordance with the risk indicator of the product specified in General attributes.
- In the event of an unfavorable development of the investment, they are able to bear the possible loss, which is illustrated by performance scenarios, see Key Information Document (KID).
- are interested in holding the product until the maturity specified in General attributes.
- This investment product is not intended for investors (negative product target market), who:
- do not have sufficient knowledge regarding structured investment instruments and shares
  - are unable to bear the loss of invested funds indicated in the Key Information Document (KID) in the event of an unfavorable development of the investment
- The client's compatibility with the product's target market will be evaluated during the purchase process.

- 
- PDCP VACCINATION AUTOCALL does not guarantee a return on the invested amount and the investor can lose the whole investment or part of it.
  - A holder of PDCP VACCINATION AUTOCALL bears the credit risk of the issuer and guarantor.
  - A holder of PDCP VACCINATION AUTOCALL is not entitled to a dividend payout from underlying shares.

**You will find more information in the leaflet**

## Description

**PDCP VACCINATION AUTOCALL with the option of automatic early repayment provides the opportunity to gain an attractive annual yield of 8% (see Note). The total yield for its three-year duration can then reach up to 24%.**

The payout of a yield and nominal value of PDCP VACCINATION AUTOCALL is derived from the price trend of the shares of three leading pharmaceutical companies, Pfizer, Moderna and Johnson & Johnson. General awareness of these companies has been raised in recent months as they were among the first in the world to place an effective COVID-19 vaccine on the market. This year it is expected that thanks to the successful vaccines, the revenues above all of Pfizer and Moderna will reach record levels. Analysts expect a gradual decrease in the revenues of these companies up to 2023 with increasing vaccine coverage rates and a decline in the pandemic.

Issuer: Goldman, Sachs & Co. Wertpapier GmbH  
 Guarantor: The Goldman Sachs Group, Inc. (S&P's BBB+ / Moody's A3 / Fitch A)  
 Underlying shares: Pfizer Inc., Moderna Inc. and Johnson & Johnson

**Subscription period: 21 September 2021 (9.00) – 4 October 2021 (16.00)**

**You will find more information in the leaflet**

### Payment notes

**How does Prémiový dluhový cenný papír VACCINATION AUTOCALL work?**

- The payout of the yield and nominal value of PDCP VACCINATION AUTOCALL depends on the trend the market rates of the shares of Pfizer Pfizer, Moderna and Johnson & Johnson.
- For the time of its duration PDCP VACCINATION AUTOCALL can be automatically repaid early annually provided that the value of each individual underlying share at the observation date will be equal or higher than the comparative value of an underlying share at a relevant observation date.
- If the automatic early repayment condition isn't met, PDCP VACCINATION AUTOCALL continues to the next possible repayment date.
- If PDCP VACCINATION AUTOCALL is automatically repaid early, the investor will receive its nominal value and a yield of 8% for each year that elapsed from the issue date.
- If there is no automatic early repayment and at the date of fixing the closing value of individual underlying shares the value of any of them doesn't fall below the barrier of 55% of its initial value, the nominal value of the Premium Bond and a total yield of 24% (equivalent of three annual yields in the amount of 8% (see Note)) shall be paid out at the maturity date.
- If there is no automatic early repayment and the price of at least one underlying share falls below the barrier of 55% of its initial value on the day of fixing the closing value of the individual underlying shares and the closing value of any of the remaining shares will not be equal or higher than 80% of its initial value, the payout of the nominal value of PDCP VACCINATION AUTOCALL on the maturity date will be decreased by the loss of the worst of the three shares from the date of fixing its initial value to the date of fixing its closing value. The investor will lose more than 45% of his investment and will not be paid out any yield.

**For more information see the leaflet**

### Settlement

- Maturity date is on 11 October 2024
- Česká spořitelna pays out the yield and nominal value
- It takes 3 working days to settle the buying and selling of the Premium Bond

### Secondary market

- Minimum purchased amount: 1 piece
- Price for the provision of early redemption: 2% of the transaction volume
- Price at subscription: 100%, free of charge
- Liquidity: daily according to current market prices shown in the Exchange Rate List of Česká spořitelna, a.s.

*Note: PDCP VACCINATION AUTOCALL makes one-off payouts of possible yields at its early or regular maturity, whereas no compound interest is applied.*

*Note 2: The initial value will be calculated by the provider based on the closing prices of the underlying assets on 4 October 2021.*

*Note 3: The risk weight is on a scale from 1 to 7 from the potentially lower risk and yield 1 to the potentially higher risk and yield 7 provided that you keep the asset until the maturity date. The actual risk may differ considerably if you sell early. The risk-weighted asset is a guide for the comparison of the risk rate of this product with others. It shows how likely it is for you to lose money as a consequence of a fluctuation on the markets, or because the issuer will not be able to pay out the money.*

*Note 4: An accurate statement of product costs is available in the Subscription Order for PDCP VACCINATION AUTOCALL.*

## Disclaimer

In the period before maturity, the bond price can fluctuate above and below the bond face value depending on the development of the interest rate and underlying asset. A bond can be sold even before the maturity date, for the price pursuant to the pricelist of the issuer. Our consultants will give you detail information on the advantages and risks of investment in bonds. The information sources used are generally regarded as reliable, although Česká spořitelna and Erste Group Bank AG cannot guarantee the correctness and completeness of the information contained therein. The aim of this web page is to give information on the services and products contained therein; it is not a binding proposal establishing any rights and obligations for participants. All information you can find here is of informative nature only. Before using the web page for investment, a specialized Česká spořitelna consultant should be consulted.